Isala

Running trials

• Not yet recruiting

  Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer

  NCT07846046· Source

• Recruiting

  Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation

  NCT07556887· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Recruiting

  Ultrasound of the Diaphragm Excursion Ratio as Physiological Biomarker in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

  NCT07259174· Source

• Recruiting

  OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

  NCT06476119· Source

• Recruiting

  Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC

  NCT06111807· Source

• Recruiting

  Observational Dutch Young Symptomatic StrokE studY - nEXT

  NCT05853796· Source

• Recruiting

  National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

  NCT05326620· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

  NCT04825743· Phase 3· Source

• Recruiting

  Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision

  NCT05772923· Source

• Recruiting

  Prospective Bladder Cancer Infrastructure (ProBCI)

  NCT04503577· Source

• Active, not recruiting

  Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

  NCT03425838· Phase 3· Source

• Recruiting

  Prospective Data Collection Initiative on Colorectal Cancer

  NCT02070146· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Lung cancer2 recruiting
• Stroke2 recruiting
• Bladder cancer1 recruiting
• COPD1 recruiting
• Kidney cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

  NCT04889183· Phase 3· Source

• Completed

  Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)

  NCT04437303· Phase 4· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source

• Completed

  Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of Atrial Fibrillation

  NCT02726698· Source